|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Supplementary material.  Table S1. Antibiotic susceptibility profile to 11 antibiotics agents against *Burkholderia cepacia* complex isolates collected from cystic fibrosis patients during 2007-2017. | | | | | |
| Antimicrobial agent | Interpretation | *B. cenocepacia* | *B. vietnamiensis* | *B. multivorans* | BCC |
| CAZ | S | 58% (33) | 10% (2) | 80% (4) | 86% (12) |
| I | 12% (7) | 0% | 0% | 0% |
| R | 30% (17) | 90% (18) | 20% (1) | 14% (2) |
| FEP | S | 69% (9) | 75% (6) | 67% (2) | 20% (1) |
| I | 8% (1) | 25% (2) | 0% | 0% |
| R | 23% (3) | 0% | 33% (1) | 80% (4) |
| MEM | S | 32% (18) | 45% (9) | 80% (4) | 93% (13) |
| I | 12% (7) | 35% (7) | 0% | 7% (1) |
| R | 56% (32) | 20% (4) | 20% (1) | 0% |
| IMP | S | 5% (1) | 88% (7) | 0% | 13% (1) |
| I | 5% (1) | 0% | 0% | 13% (1) |
| R | 90% (17) | 13% (1) | 100% (5) | 75% (6) |
| DOR | S | 25% (6) | 14% (1) | - | 38% (3) |
| I | 4% (1) | 0% | - | 38% (3) |
| R | 71% (17) | 86% (6) | - | 25% (2) |
| MIN | S | 6% (3) | 50% (10) | 100% (2) | 75% (9) |
| I | 20% (10) | 25% (5) | 0% | 17% (2) |
| R | 74% (37) | 25% (5) | 0% | 8% (1) |
| LVX | S | 29% (6) | 0% | - | 0% |
| I | 19% (4) | 0% | - | 50% (2) |
| R | 52% (11) | 100% (5) | - | 50% (2) |
| CIP | S | 30% (3) | 0% | 0% | 25% (2) |
| I | 20% (2) | 0% | 0% | 38% (3) |
| R | 50% (5) | 100% (2) | 100% (3) | 38% (3) |
| TMS | S | 6%(3) | 10% (2) | 100% (5) | 8% (1) |
| I | 4%(2) | 0% | 0% | 0% |
| R | 90% (47) | 90% (18) | 0% | 92% (12) |
| GEN | S | 0% | 0% | 0% | 0% |
| I | 0% | 0% | 0% | 0% |
| R | 100% (16) | 100% (5) | 100% (3) | 100% (10) |
| AKN | S | 0% | 0% | 0% | 0% |
| I | 0% | 0% | 0% | 0% |
| R | 100% (36) | 100% (11) | 100% (3) | 100% (9) |
| Antibiotics: ceftazidime – CAZ (30μg), meropenem – MEM (10μg), minocycline – MIN (30μg) and trimethoprim/sulfamethoxazole – TMS, cefepime – FEP (30μg), doripenem – DOR (30μg), imipenem –IMP (10μg), amikacin – AKN (30μg), gentamicin – GEN (10μg), ciprofloxacin – CIP (5μg) and levofloxacin – LVX (5μg). S, sensitive; I, intermediate; R, resistant according to CLSI(4,9), ( ) number of isolated. - , not analyzed. | | | | | |